- Home
- BUJA vs ALVR Comparison
BUJA vs ALVR Comparison
Compare BUJA & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- ALVR
- Stock Information
- Founded
- BUJA 2022
- ALVR 2013
- Country
- BUJA Malaysia
- ALVR United States
- Employees
- BUJA N/A
- ALVR N/A
- Industry
- BUJA Blank Checks
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BUJA Finance
- ALVR Health Care
- Exchange
- BUJA Nasdaq
- ALVR Nasdaq
- Market Cap
- BUJA N/A
- ALVR 87.7M
- IPO Year
- BUJA 2023
- ALVR 2020
- Fundamental
- Price
- BUJA $10.96
- ALVR $0.94
- Analyst Decision
- BUJA
- ALVR Sell
- Analyst Count
- BUJA 0
- ALVR 5
- Target Price
- BUJA N/A
- ALVR $1.00
- AVG Volume (30 Days)
- BUJA 2.7K
- ALVR 155.6K
- Earning Date
- BUJA 01-01-0001
- ALVR 11-04-2024
- Dividend Yield
- BUJA N/A
- ALVR N/A
- EPS Growth
- BUJA N/A
- ALVR N/A
- EPS
- BUJA 0.29
- ALVR N/A
- Revenue
- BUJA N/A
- ALVR N/A
- Revenue This Year
- BUJA N/A
- ALVR N/A
- Revenue Next Year
- BUJA N/A
- ALVR N/A
- P/E Ratio
- BUJA $37.13
- ALVR N/A
- Revenue Growth
- BUJA N/A
- ALVR N/A
- 52 Week Low
- BUJA $10.30
- ALVR $0.58
- 52 Week High
- BUJA $12.18
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- ALVR 69.10
- Support Level
- BUJA $10.85
- ALVR $0.74
- Resistance Level
- BUJA $10.85
- ALVR $0.91
- Average True Range (ATR)
- BUJA 0.00
- ALVR 0.06
- MACD
- BUJA -0.00
- ALVR 0.01
- Stochastic Oscillator
- BUJA 87.50
- ALVR 94.50
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.